Physician profile
Teri A Longacre
NPI 1528120896
$60,165.78
in general payments reported to CMS, 2019-2025
8 companies · $42K in 2025
The $42K reported for 2025 was more than what 98% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,125 · 2021: $1,125 · 2023: $1,231 · 2024: $1,245 · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Honoraria: $1,245 · Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,309.75 |
| Honoraria | $1,245.00 |
| Food and Beverage | $111.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Europe Ltd | $38,758.50 | 2025 | Vyloy |
| Astellas Pharma US INC | $8,293.47 | 2019 | |
| Merck Sharp & Dohme LLC | $7,206.06 | 2019-2021 | |
| Verastem, INC. | $3,038.75 | 2025 | Avmapki Fakzynja Co-Pack |
| Astrazeneca Pharmaceuticals Lp | $1,512.50 | 2023-2025 | |
| Blueprint Medicines Corporation | $1,245.00 | 2024 | Ayvakit |
| Glaxosmithkline, LLC. | $90.33 | 2025 | |
| Hologic Sales and Service, LLC | $21.17 | 2023 | Panther Fusion, Trident Specimen Radiography System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teri Longacre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.